Science Corp Wins CE Mark, Launches PRIMA Retinal Implant in Europe

Geographic atrophy, an advanced form of dry age-related macular degeneration, destroys central retinal photoreceptors and can strip patients of the ability to read or recognize faces. More than 5 million people are affected worldwide. Science Corp’s PRIMA pairs camera-equipped glasses and a pocket processor with a 2-by-2-millimeter, 378-pixel photovoltaic implant under the retina, stimulating remaining cells without brain surgery and marking a rare commercial breakthrough for brain-computer interfaces.

Science Corp said on July 22, 2026, that DEKRA granted PRIMA a CE mark under the European Union Medical Device Regulation, clearing commercial availability in 30 European countries. The first commercial implant is expected soon in Germany, while reimbursement filings and clinical-site activations proceed. In a 38-patient trial across 17 sites in five countries, average acuity improved by 25.5 ETDRS letters after 12 months; 80% achieved a clinically meaningful gain and 84% reported reading letters, numbers and words. Science raised $230 million in March to fund commercialization.